Following behind a blockbuster is no easy task, but with a European Commission decision on Wednesday in favor of the vaccine, Merck's Gardasil 9 may just be up to the challenge of succeeding Gardasil.
The recommended schedule for HPV vaccination is two or three doses, but some patients never make it back for all of the shots. This may cease to be a concern if future trials prove what scientists reported on Wednesday: A single dose of GlaxoSmithKline's Cervarix could work as well as the recommended two- or three-dose regimens at preventing the majority of cervical cancers.
A new analysis shows that healthcare systems can prevent throat cancer cases and save in long-term treatment costs by covering the HPV vaccine in young boys. Currently, Australia, Canada and the United States recommend the jab for boys, but only cover it for young girls.
Merck's new-and-improved Gardasil is making headway in Europe with the word late last week that the European Medicines Agency has recommended the jab against 9 types of human papillomavirus and will send its blessing to the European Commission.
Serum Institute of India, which has a history of undercutting its competition in the vaccine sphere, is expanding this undercutting game to HPV. Its low-cost competitor to Merck's Gardasil could hit the market in late 2018 at one-third the price.
The Serum Institute of India, the world's fifth largest vaccinemaker by volume, is eyeing newer vaccines, including one for the human papillomavirus expected to be launched by late 2018 and sell at a third of the price of Merck & Co.'s blockbuster Gardasil, Bloomberg reported.
Merck and partner Sanofi can breathe easy: According to a new study, their blockbuster Gardasil isn't linked to an increased risk of multiple sclerosis.
Merck's Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.
Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide, new research shows. But getting there will be no walk in the park. First, the company will have to solve some uptake problems that have been plaguing the candidate's predecessor, Gardasil, since it rolled out in 2006.
The debate around use of Merck's Gardasil in the United Kingdom is ratcheting up ahead of a meeting of the Joint Committee on Vaccinations and Immunisation (JCVI) in October.